Role of catechol-O-methyltransferase in the disposition of luteolin in rats

Drug Metabolism and Disposition

Volumn 39, Issue 4, 2011, Pages 667-674

  Chen, Zhongjian ^a   Chen, Meng ^a   Pan, Hao ^a   Sun, Siyuan ^a   Li, Liping ^a   Zeng, Su ^a   Jiang, Huidi ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CHRYSOERIOL; DIOSMETIN; DRUG METABOLITE; ENTACAPONE; LUTEOLIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG URINE LEVEL; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; JEJUNUM; KIDNEY PARENCHYMA; LIVER MICROSOME; LIVER PARENCHYMA; LUNG PARENCHYMA; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; METHYLATION; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TISSUE HOMOGENATE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; LUTEOLIN; MALE; METABOLIC DETOXICATION, PHASE I; METHYLATION; MICROSOMES, LIVER; NITRILES; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; RATTUS;

EID: 79952851325     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037333     Document Type: Article

References (35)

1. Androutsopoulos VP, Papakyriakou A, Vourloumis D, Tsatsakis AM, and Spandidos DA (2010) Dietary flavonoids in cancer therapy and prevention: substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmacol Ther 126:9-20.
2. Bonifácio MJ, Loureiro AI, Torrão L, Fernandes-Lopes C, Wright L, Pinho MJ, and Soares-da-Silva P (2009) Species differences in pharmacokinetic and pharmacodynamic properties of nebicapone. Biochem Pharmacol 78:1043-1051.
3. Busse D, Cosme J, Beaune P, Kroemer HK, and Eichelbaum M (1995) Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 353:116-121. (Pubitemid 26009826)
4. Cha BY, Shi WL, Yonezawa T, Teruya T, Nagai K, and Woo JT (2009) An inhibitory effect of chrysoeriol on platelet-derived growth factor (PDGF)-induced proliferation and PDGF receptor signaling in human aortic smooth muscle cells. J Pharmacol Sci 110:105-110.
5. Chen T, Li LP, Lu XY, Jiang HD, and Zeng S (2007) Absorption and excretion of luteolin and apigenin in rats after oral administration of Chrysanthemum morifolium extract. J Agric Food Chem 55:273-277. (Pubitemid 46586306)
6. de Boer VC, Dihal AA, van der Woude H, Arts IC, Wolffram S, Alink GM, Rietjens IM, Keijer J, and Hollman PC (2005) Tissue distribution of quercetin in rats and pigs. J Nutr 135:1718-1725. (Pubitemid 40980724)
7. Gradolatto A, Canivenc-Lavier MC, Basly JP, Siess MH, and Teyssier C (2004) Metabolism of apigenin by rat liver phase I and phase II enzymes and by isolated perfused rat liver. Drug Metab Dispos 32:58-65. (Pubitemid 38112536)
8. Heim KE, Tagliaferro AR, and Bobilya DJ (2002) Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships. J Nutr Biochem 13:572-584. (Pubitemid 35246546)
9. Hsu YL and Kuo PL (2008) Diosmetin induces human osteoblastic differentiation through the protein kinase C/p38 and extracellular signal-regulated kinase 1/2 pathway. J Bone Miner Res 23:949-960.
10. +/glucose transporter when expressed in Xenopus laevis oocytes, but effectively inhibit electrogenic glucose uptake. J Pharmacol Exp Ther 322:829-835.
11. Lau EY and Bruice TC (1998) Importance of correlated motions in forming highly reactive near attack conformations in catechol O-methyltransferase. J Am Chem Soc 120:12387-12394. (Pubitemid 29003593)
12. Li L, Jiang H, Wu H, and Zeng S (2005) Simultaneous determination of luteolin and apigenin in dog plasma by RP-HPLC. J Pharm Biomed Anal 37:615-620. (Pubitemid 40312310)
13. Li LP and Jiang HD (2006) Determination and assay validation of luteolin and apigenin in human urine after oral administration of tablet of Chrysanthemum morifolium extract by HPLC. J Pharm Biomed Anal 41:261-265.
14. Liu Z, Song XD, Xin Y, Wang XJ, Yu H, Bai YY, Liu JH, Zhang CN, and Hui RT (2009) Protective effect of chrysoeriol against doxorubicin-induced cardiotoxicity in vitro. Chin Med J (Engl) 122:2652-2656.
15. López-Lázaro M (2009) Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem 9:31-59.
16. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melén K, Julkunen I, and Taskinen J (1995) Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34:4202-4210.
17. Lu H, Meng X, and Yang CS (2003) Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate. Drug Metab Dispos 31:572-579. (Pubitemid 36444166)
18. Lu XY, Sun DL, Chen ZJ, Chen T, Li LP, Xu ZH, Jiang HD, and Zeng S (2010) Relative contribution of small and large intestine to deglycosylation and absorption of flavonoids from Chrysanthemum morifolium extract. J Agric Food Chem 58:10661-10667.
19. Männistö PT and Kaakkola S (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51:593-628.
20. Ng SP, Wong KY, Zhang L, Zuo Z, and Lin G (2004) Evaluation of the first-pass glucuronidation of selected flavones in gut by Caco-2 monolayer model. J Pharm Pharm Sci 8:1-9. (Pubitemid 41528864)
21. Palma PN, Bonifácio MJ, Loureiro AI, Wright LC, Learmonth DA, and Soares-da-Silva P (2003) Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor. Drug Metab Dispos 31:250-258. (Pubitemid 36249678)
22. Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, and Gordin A (2000) The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry 68:589-594. (Pubitemid 30248823)
23. Rueff J, Gaspar J, and Laires A (1995) Structural requirements for mutagenicity of flavonoids upon nitrosation. A structure-activity study. Mutagenesis 10:325-328.
24. Seelinger G, Merfort I, and Schempp CM (2008a) Anti-oxidant, anti-inflammatory and antiallergic activities of luteolin. Planta Med 74:1667-1677.
25. Seelinger G, Merfort I, Wölfle U, and Schempp CM (2008b) Anti-carcinogenic effects of the flavonoid luteolin. Molecules 13:2628-2651.
26. Sesink AL, Arts IC, Faassen-Peters M, and Hollman PC (2003) Intestinal uptake of quercetin-3-glucoside in rats involves hydrolysis by lactase phlorizin hydrolase. J Nutr 133:773-776. (Pubitemid 36268353)
27. Shimoi K, Okada H, Furugori M, Goda T, Takase S, Suzuki M, Hara Y, Yamamoto H, and Kinae N (1998) Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Lett 438:220-224. (Pubitemid 28529277)
28. Singh A, Naidu PS, and Kulkarni SK (2003) Quercetin potentiates L-dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition. Pharmacology 68:81-88. (Pubitemid 36469855)
29. Soares-da-Silva P, Vieira-Coelho MA, and Parada A (2003) Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenylethanone). Pharmacol Toxicol 92:272-278. (Pubitemid 36734985)
30. Vidgren J (1998) X-ray crystallography of catechol O-methyltransferase: perspectives for targetbased drug development. Adv Pharmacol 42:328-331.
31. Wright B, Gibson T, Spencer J, Lovegrove JA, and Gibbins JM (2010) Platelet-mediated metabolism of the common dietary flavonoid, quercetin. PLoS One 5:e9673.
32. Xia ZL, Ying JY, Sheng R, Zeng S, Hu YZ, and Yao TW (2007) In vitro metabolism of BYZX in human liver microsomes and the structural elucidation of metabolite by liquid chromatography-mass spectrometry method. J Chromatogr B Analyt Technol Biomed Life Sci 857:266-274. (Pubitemid 47444584)
33. Yee S (1997) In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth. Pharm Res 14:763-766.
34. Zhou P, Li LP, Luo SQ, Jiang HD, and Zeng S (2008) Intestinal absorption of luteolin from peanut hull extract is more efficient than that from individual pure luteolin. J Agric Food Chem 56:296-300. (Pubitemid 351154766)
35. Zhu BT, Ezell EL, and Liehr JG (1994) Catechol-O-methyltransferase- catalyzed rapid O-methylation of mutagenic flavonoids. Metabolic inactivation as a possible reason for their lack of carcinogenicity in vivo. J Biol Chem 269:292-299.